Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer

被引：2

作者：

Lin, Gen ^{[1
]}

Wang, Zhijie ^{[2
]}

Chu, Qian ^{[3
]}

Hu, Yi ^{[4
]}

Huang, Dingzhi ^{[5
]}

Wang, Jun ^{[6
]}

Yang, Fan ^{[7
]}

Zhong, Wenzhao ^{[8
]}

Zhou, Chengzhi ^{[9
]}

Zhu, Bo ^{[10
]}

Ai, Xinghao ^{[11
]}

Cao, Baoshan ^{[12
]}

Cao, Yabing ^{[13
]}

Chen, Mingqiu ^{[14
]}

Chen, Xiaohui ^{[15
]}

Chu, Tianqing ^{[16
]}

Duan, Jianchun ^{[2
]}

Fan, Yun ^{[17
]}

Fang, Yong ^{[18
]}

Feng, Shuitu ^{[19
]}

Feng, Weineng ^{[20
]}

Guo, Hui ^{[21
]}

Han, Chengbo ^{[22
]}

He, Yong ^{[23
]}

Hong, Shaodong ^{[24
]}

Hu, Jie ^{[25
]}

Huang, Meijuan ^{[26
]}

Huang, Yan ^{[24
]}

Jiang, Da ^{[27
]}

Jiang, Kan ^{[1
]}

Jiang, Richeng ^{[5
]}

Jin, Bo ^{[28
]}

Jin, Shi ^{[29
]}

Li, Jisheng ^{[30
]}

Li, Min ^{[31
]}

Li, Ziming ^{[11
]}

Li, Chao ^{[32
]}

Lin, Jie ^{[33
]}

Liu, Anwen ^{[34
]}

Liu, Si-Yang Maggie ^{[35
]}

Yutao, Liu ^{[2
]}

Liu, Zhefeng ^{[4
]}

Liu, Zhe ^{[36
]}

Liu, Zhenhua ^{[37
]}

Liu, Zhentian ^{[38
]}

Liu, Zhigang ^{[39
]}

Lu, Yuping ^{[40
]}

Lv, Tangfeng ^{[41
]}

Ma, Zhiyong ^{[42
]}

Miao, Qian ^{[1
]}

机构：

[1] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Dept Thorac Oncol, Fuzhou, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China

[3] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China

[4] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China

[5] Tianjin Med Univ Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China

[6] Shandong First Med Univ, Shandong Prov Qianfoshan Hosp, Dept Radiol, Affiliated Hosp 1, Jinan, Peoples R China

[7] Peking Univ Peoples Hosp, Dept Thorac Surg, Beijing, Peoples R China

[8] Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangzhou, Peoples R China

[9] First Affiliated Hosp Guangzhou Med Univ, Guangzhou Inst Resp Hlth, Natl Clin Res Ctr Resp Dis, Natl Ctr Resp Med,State Key Lab Resp Dis,Dept Cri, Guangzhou, Peoples R China

[10] Army Med Univ, Xinqiao Hosp, Inst Canc, Chongqing, Peoples R China

[11] Shanghai Jiao Tong Univ, Sch Med, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[12] Peking Univ Third Hosp, Dept Med Oncol & Radiat Sickness, Beijing, Peoples R China

[13] Kiang Wu Hosp, Dept Oncol, Macau, Peoples R China

[14] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China

[15] Fujian Med Univ, Fujian Canc Hosp, Dept Thorac Surg, Clin Oncol Sch, Fuzhou, Peoples R China

[16] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Resp Dept, Sch Med, Shanghai 200030, Peoples R China

[17] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[18] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Med Oncol, Hangzhou, Peoples R China

[19] Fudan Univ, Dept Radiat Oncol, Xiamen branch, Shanghai Canc Ctr, Xiamen, Peoples R China

[20] First Peoples Hosp Foshan, Dept Radiat Oncol, Foshan, Peoples R China

[21] First Affiliated Hosp Xian Jiaotong Univ, Dept Med Oncol, Xian 710061, Peoples R China

[22] Shengjing Hosp China Med Univ, Dept Oncol, Shenyang, Peoples R China

[23] Army Med Univ, Xinqiao Hosp, Dept Resp Med, Chongqing, Peoples R China

[24] Sun Yat sen Univ Canc Ctr, State Key Lab Oncol Southern China, Guangzhou, Peoples R China

[25] Fudan Univ, Shanghai Zhongshan Hosp, Canc Ctr, Shanghai, Peoples R China

[26] Sichuan Univ, West China Hosp, Canc Ctr, Div Thorac Tumor Multimodal Treatment, Chengdu, Peoples R China

[27] Fourth Affiliated Hosp Hebei Med Univ, Dept Orthoped, Shijiazhuang, Herts, Peoples R China

[28] First Hosp China Med Univ, Dept Med Oncol, Shenyang, Peoples R China

[29] Chinese Acad Med Sci & Perking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Shenzhen 518116, Peoples R China

[30] Qilu Hosp Shandong Univ, Dept Med Oncol, Jinan, Peoples R China

[31] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Peoples R China

[32] Fujian Med Univ, Fujian Canc Hosp, Dept Pathol, Clin Oncol Sch, Fuzhou, Peoples R China

[33] Second Affiliated Hosp Kunming Med Univ, Dept Hematol, Kunming, Peoples R China

[34] Second Affiliated Hosp Nanchang Univ, Dept Vasc Surg, Nanchang, Peoples R China

[35] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[36] Capital Med Univ, Beijing Chest Hosp, Dept Med Oncol, Beijing, Peoples R China

[37] Fujian Med Univ, Fujian Prov Hosp, Shengli Clin Med Coll, Dept Oncol, Fuzhou, Peoples R China

[38] Jiangxi Canc Hosp, Dept Thorac Oncol, Nanchang, Peoples R China

[39] Southern Med Univ, Affiliated Dongguan Hosp, Ctr Canc, Dongguan, Guangdong, Peoples R China

[40] Fujian Med Univ, Fujian Canc Hosp, Dept Abdominal Oncol, Clin Oncol Sch, Fuzhou, Peoples R China

[41] Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing, Peoples R China

[42] Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, Dept Resp Med, Zhengzhou, Peoples R China

[43] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China

[44] Cent South Univ, Dept Thorac Med Oncol, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China

[45] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Tianjin, Peoples R China

[46] Zhejiang Univ, Affiliated Hosp 1, Dept Nucl Med, Hangzhou, Zhejiang, Peoples R China

[47] Army Med Univ, Daping Hosp, Dept Radiat Oncol, Chongqing, Peoples R China

[48] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China

[49] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Med Oncol,Jiangsu Canc Hosp, Nanjing, Peoples R China

[50] Zhejiang Canc Hosp, Dept Clin Trial, Hangzhou, Peoples R China

来源：

THORACIC CANCER | 2024年 / 15卷 / 05期

关键词：

ICI; NSCLC; re-challenge; NIVOLUMAB; PEMBROLIZUMAB; EFFICACY; PLACEBO; NSCLC;

D O I：

10.1111/1759-7714.15209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD-1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

引用

页码：419 / 426

页数：8

共 50 条

[41] Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
Miura, Yosuke
Kasahara, Norimitsu
Sunaga, Noriaki
[J]. TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S628 - S632
[42] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
Abdayem, Pamela
Planchard, David
[J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
[43] Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Zhenbin Qiu
Zihao Chen
Chao Zhang
Wenzhao Zhong
[J]. Experimental Hematology & Oncology, 8
[44] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
Wang, Shuai
Hao, Jiatao
Wang, Hao
Fang, Yong
Tan, Lijie
[J]. ONCOIMMUNOLOGY, 2018, 7 (08):
[45] Immune checkpoint inhibitors in therapy of non-small cell lung cancer (a review)
Kolesnik, O. P.
Mykhailychenko, V. V.
[J]. ZAPOROZHYE MEDICAL JOURNAL, 2021, 23 (03) : 418 - 425
[46] Checkpoint inhibitors in older patients with advanced non-small cell lung cancer
Reale, Maria Lucia
Romano, Gianpiero Diego
Paolelli, Loretta
Leo, Silvana
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 188
[47] Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer
Katayama, Yuki
Shimamoto, Takayuki
Yamada, Tadaaki
Takeda, Takayuki
Yamada, Takahiro
Shiotsu, Shinsuke
Chihara, Yusuke
Hiranuma, Osamu
Iwasaku, Masahiro
Kaneko, Yoshiko
Uchino, Junji
Takayama, Koichi
[J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
[48] Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer
Jones, L.
Rittberg, R.
Leung, B.
Shokoohi, A.
Pender, A.
Wong, S.
Al-Hashami, Z.
Wang, Y.
Ho, C.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S444 - S444
[49] Safety of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Abnormalities or Disease
Nakazawa, S.
Kato, M.
Soma, S.
Namba, H.
Arai, Y.
Motomura, H.
Ochi, Y.
Kurokawa, K.
Sumiyoshi, I.
Watanabe, J.
Ihara, H.
Asao, T.
Shimada, N.
Togo, S.
Sasaki, S.
Takahashi, K.
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[50] Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study
Yan, Xiaoqi
Zhao, Luqing
Wu, Fei
Shen, Bo
Zhou, Guoren
Feng, Jifeng
Yue, Chao
Zhu, Jingni
Yu, Shaorong
Zhu, Jingni
[J]. JOURNAL OF THORACIC DISEASE, 2024, 16 (03) : 1787 - 1803

← 1 2 3 4 5 →